Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Pharma stories

Sep 29, 2026

Novo Nordisk licenses experimental GLP-1 obesity pill from Hengrui for up to $2.6 billion

Novo Nordisk will pay up to $2.6 billion to license HRS-1596, an experimental oral obesity drug from China's Jiangsu Hengrui Pharmaceuticals, marking the company's second major deal since a key investor meeting.

Sep 29, 2026·3 sources
00
Sep 28, 2026

AstraZeneca invests $2 billion in Summit Therapeutics for cancer drug collaboration

AstraZeneca is investing $2 billion in Summit Therapeutics and collaborating on clinical trials testing their cancer treatments together, with AstraZeneca taking an equity stake in the biotech company.

Sep 28, 2026·5 sources
00

Merck licenses KRAS G12D cancer drug from SciBrunch for $400 million upfront

Merck agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug targeting the KRAS G12D mutation, continuing a trend of U.S. drugmakers licensing China-developed therapies.

Sep 28, 2026·3 sources
00
Sep 26, 2026

TikTok to pay Alabama $100 million in child safety settlement

TikTok and ByteDance agreed to pay Alabama at least $100 million and enact limits for teen users, avoiding a trial over claims related to child safety on the platform.

Sep 26, 2026·2 sources
00
Sep 25, 2026

Genentech inks $1.5 billion bispecific antibody deal with Earendil Labs

Roche's Genentech is paying Earendil Labs $55 million upfront in a research collaboration to discover and develop multiple bispecific antibody cancer therapies. The oncology-focused deal includes milestone payments that could bring its total value to over $1.5 billion.

Sep 25, 2026·4 sources
00

Novo Nordisk signs $1.3 billion deal with Nanexa for long-acting drug delivery technology

Novo Nordisk agreed to pay up to €1.165 billion ($1.3 billion) for a global license to Swedish biotech Nanexa's PharmaShell drug delivery technology, which could enable obesity medications requiring injections only once every few months. Nanexa shares surged more than 110% on the announcement.

Sep 25, 2026·5 sources
00

ADARx prices $446 million IPO as RNAi biotech

ADARx Pharmaceuticals priced a $446.3 million Nasdaq IPO, becoming the first RNAi-focused biotech to go public in the U.S. in more than a year and continuing strong momentum in biotech IPO activity.

Sep 25, 2026·2 sources
00
Sep 24, 2026

Eli Lilly strikes $3.35 billion drug development deal with InnoCare Pharma in China

Eli Lilly announced a partnership with China-based InnoCare Pharma worth up to $3.35 billion, marking the pharmaceutical giant's fourth China-focused alliance since January 2025. The deal focuses on oncology and autoimmune drug development, continuing Lilly's aggressive dealmaking strategy in the region.

Sep 24, 2026·7 sources
00

FDA approves Eli Lilly's Onswik once-weekly insulin for type 2 diabetes

The U.S. Food and Drug Administration has approved Eli Lilly's Onswik, a once-weekly basal insulin injection for adults with type 2 diabetes. The approval offers patients an alternative to daily long-acting insulin injections, potentially reducing the number of injections by more than 300 per year.

Sep 24, 2026·5 sources
00

Merck's remigromig meets primary endpoint in diabetic macular edema trial amid safety concerns

Merck announced that remigromig, a tri-specific antibody acquired in a $1.3 billion buyout, achieved its primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for diabetic macular edema. However, language regarding the drug's safety profile has raised concerns among analysts.

Sep 24, 2026·4 sources
00

Roche signs drug discovery deal with Atavistik Bio worth up to $2 billion

Swiss drugmaker Roche has entered a partnership with Atavistik Bio potentially worth nearly $2 billion, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases. The deal includes $70 million upfront with an additional $1.9 billion in potential milestone payments.

Sep 24, 2026·6 sources
00
Sep 23, 2026

Roche kidney disease drug succeeds in Phase 3 trial for IgA nephropathy

Roche's experimental RNA drug sefaxersen significantly reduced proteinuria in a late-stage trial for IgA nephropathy, positioning the company to bring a new treatment to market for the autoimmune kidney disease that currently has limited approved therapies.

Sep 23, 2026·3 sources
00
Sep 22, 2026

Vertex Pharmaceuticals reports positive phase 2b trial results for inaxaplin in kidney disease

Vertex Pharmaceuticals announced positive results from its phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD), including patients with modest proteinuria and those with type 2 diabetes. The company is positioning the drug for a broad kidney disease label ahead of a key readout next year.

Sep 22, 2026·6 sources
00

Novo Nordisk CEO says weight-loss pills could capture 50% of obesity market by 2030

Novo Nordisk CEO Mike Doustdar told Reuters that oral weight-loss medications could represent up to half of the global obesity drug market by 2030, as the Danish drugmaker positions itself for a shift toward pill-based treatments alongside its injectable GLP-1 drugs.

Sep 22, 2026·3 sources
00

Roche's obesity drug enicepatide cuts body weight 15.5% in mid-stage trial

Roche's experimental obesity shot enicepatide reduced blood sugar and body weight by 15.5% in type-2 diabetes patients in a mid-stage trial, with a meaningful proportion reaching normalized glucose levels within less than a year of treatment.

Sep 22, 2026·2 sources
00
Sep 21, 2026

Hackensack Meridian Health CEO Robert Garrett to retire next summer

Robert C. Garrett, chief executive of New Jersey-based nonprofit health system Hackensack Meridian Health, will retire next summer. The health system's board of directors will begin a search for his successor.

Sep 21, 2026·2 sources
00

Johnson & Johnson cuts 87 jobs in New Jersey workforce

Johnson & Johnson has laid off 87 employees from its New Jersey operations in 2026, marking another round of workforce reductions for the pharmaceutical giant in the state.

Sep 21, 2026·1 source
00

Oura seeks to raise $2.2 billion in IPO with most proceeds going to existing shareholders

Smart ring maker Oura has launched its U.S. initial public offering targeting a valuation of up to $15.62 billion, but the company will receive little to none of the $2.2 billion raised as existing investors sell their shares. The Finnish health and fitness wearables company is offering 50 million shares priced between $40 and $44 each.

Sep 21, 2026·7 sources
00

Novo Nordisk's CagriSema outperforms Eli Lilly in diabetes trial as 700,000 seniors start GLP-1s under Medicare

Novo Nordisk announced its experimental drug CagriSema achieved 12.4% average weight loss in diabetes patients, surpassing Eli Lilly's rival treatment. Meanwhile, Eli Lilly reported 700,000 new seniors have begun GLP-1 treatments since Medicare coverage for obesity drugs launched in July, with 70% choosing Lilly medications.

Sep 21, 2026·2 sources
00

Telix acquires ITM for $1.65 billion to create radiopharmaceutical powerhouse

Telix Pharmaceuticals is acquiring ITM for $1.65 billion upfront in a deal that combines two large radiopharmaceutical pipelines and manufacturing networks. Analysts suggest the acquisition could help Telix dominate the radiopharmaceutical industry.

Sep 21, 2026·1 source
00

Paramount settles state lawsuits, clearing path for $110 billion Warner Bros. Discovery acquisition

Paramount Skydance reached settlements with California and 11 other state attorneys general who sued to block its proposed $110 billion acquisition of Warner Bros. Discovery. The settlement includes terms requiring 30 films annually and penalties for non-compliance.

Sep 21, 2026·5 sources
00

Novo Nordisk's CagriSema outperforms Eli Lilly's tirzepatide in weight loss trials

Novo Nordisk announced topline results showing CagriSema achieved 12.4% weight loss versus 9.1% for tirzepatide at 60 weeks in adults with type 2 diabetes in the REIMAGINE 5 trial, and induced 21% weight loss at 68 weeks in people with overweight or obesity without diabetes in the REDEFINE trial.

Sep 21, 2026·2 sources
00

Susan Collins and members of Congress oppose White House plan for political review of NIH grants

Senator Susan Collins and other members of Congress are pushing back against a White House proposal to create a commission of political appointees to review National Institutes of Health research grants. The plan, pushed by OMB Director Russell Vought, has sparked concerns about politicization of federal biomedical research funding.

Sep 21, 2026·4 sources
00
Sep 20, 2026

Novo Nordisk cuts 13,000 jobs as CEO outlines strategy beyond weight-loss drugs

Novo Nordisk announced it cut 13,000 jobs in the past year and outlined plans to diversify beyond obesity drugs with new pipeline assets and bolt-on acquisitions. CEO Mike Doustdar faced investor skepticism about pricing power and strategy ahead of patent expiries.

Sep 20, 2026·9 sources
00
Sep 18, 2026

Two hospital systems settle US probe over transgender care billing for $9.5 million

Two major US hospital systems agreed to pay nearly $9.5 million combined to settle a Department of Justice probe into claims that the medical centers were improperly billing for gender-affirming care.

Sep 18, 2026·2 sources
00

Compass Pathways prepares psychedelic drug launch following J&J's ketamine strategy

Compass Pathways executives revealed plans to model their upcoming psychedelic treatment launch after Johnson & Johnson's strategy for Spravato, the ketamine nasal spray, as the FDA considers approval. The move comes as psychedelic therapeutics face a critical juncture following Lykos' failed MDMA therapy approval in 2024.

Sep 18, 2026·2 sources
00

WHO warns of global health workforce gap as quarter of doctors set to retire by 2030s

The World Health Organization flagged a looming shortage in medical professionals worldwide, with 25% of doctors expected to retire in the next decade while patient populations age.

Sep 18, 2026·2 sources
00

Angle Health raises $600 million at $2.7 billion valuation

Angle Health, an AI-based health benefits platform founded by two former Palantir engineers, secured $600 million in funding led by European midmarket firm Vitruvian Partners, reaching a $2.7 billion valuation. The San Francisco-based startup provides digital healthcare benefits for employers.

Sep 18, 2026·2 sources
00
Sep 17, 2026

Electra Therapeutics raises $350 million in upsized US IPO

Electra Therapeutics, a clinical-stage immunology drug developer, raised $350 million in an upsized initial public offering priced at the mid-point of its marketed range. The IPO is part of a resurgence in biotech public offerings, with nearly a dozen firms raising $300 million or more in 2026, levels not seen since 2021.

Sep 17, 2026·3 sources
00

Xenon Pharmaceuticals pauses depression drug trials over neuropsychiatric side effects

Xenon Pharmaceuticals temporarily halted new patient enrollment in clinical studies of its experimental depression drug following reports of mental health-related adverse events, causing shares to fall.

Sep 17, 2026·3 sources
00

US weighs allowing most pharma licensing deals with China

The US is developing rules for pharmaceutical companies investing in China that would likely preserve their ability to strike most licensing deals for Chinese drugs, according to sources familiar with the matter.

Sep 17, 2026·2 sources
00

Lisata acquires Marea with $225 million financing to advance cardioendocrine pipeline

Lisata Therapeutics has acquired Marea Therapeutics alongside a $225 million private placement financing to develop first-in-class medicines for cardioendocrine diseases. Marea brings multiple late-stage clinical candidates including MAR001/005 for cardiovascular and endocrine conditions.

Sep 17, 2026·2 sources
00

Judge approves CVS unit Omnicare's bankruptcy plan after $250 million sale

A Texas judge approved a wind-down bankruptcy plan for CVS Health subsidiary Omnicare LLC following the sale of its business operations for $250 million and resolution of a nearly $1 billion judgment related to improperly dispensing prescription drugs.

Sep 17, 2026·3 sources
00

Roche's Lunsumio meets primary endpoint in phase 3 follicular lymphoma trial

Roche announced that its T-cell engager Lunsumio successfully met the primary endpoint in a confirmatory phase 3 trial for earlier-line follicular lymphoma treatment. The company is now pursuing a label expansion for the drug based on these positive results.

Sep 17, 2026·2 sources
00

Biotech hedge fund launches new immunology company

A biotech-focused hedge fund has established a new company focused on immunology research and development. The venture represents the fund's move into direct company creation in the biotechnology sector.

Sep 17, 2026·1 source
00

HaloMD lobbyist defends No Surprises Act impact amid criticism of company and analysis

Patrick Velliky, HaloMD's chief external affairs officer, maintains the No Surprises Act is reducing out-of-network spending despite contradictory research, while responding to criticisms of both his analysis and the company.

Sep 17, 2026·1 source
00

Novo Nordisk signs up to $1.4B partnership with Orbis Medicines for cardiometabolic drugs

Novo Nordisk agreed to a partnership worth up to $1.4 billion with Lilly-backed Orbis Medicines to develop macrocycle pills for heart and metabolic diseases, marking Orbis' first major pharma deal.

Sep 17, 2026·2 sources
00

Roche, Dualitas partner on $1B bispecific antibody discovery deal

Roche will collaborate with Dualitas to screen over 300,000 bispecific antibody combinations for inflammatory and immunology conditions in a deal worth up to $1 billion.

Sep 17, 2026·2 sources
00

RFK Jr. appoints eight new members to US Preventive Services Task Force

Health Secretary Robert F. Kennedy Jr. named eight new members to the influential USPSTF panel after months of vacancies, filling positions on the body that determines which preventive medical care should be covered.

Sep 17, 2026·3 sources
00
Sep 16, 2026

England approves breast cancer drug Enhertu after UK-US pharma deal

England's NHS will provide AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for aggressive breast cancer after the drug was previously rejected twice. The approval follows an agreement reached with the companies.

Sep 16, 2026·3 sources
00

Novartis acquires blood-brain barrier technology for $125M amid pipeline setbacks

Novartis is purchasing Sironax's platform technology for $125 million to transport drugs across the blood-brain barrier, as the pharmaceutical giant faces multiple neuroscience pipeline failures including the halt of an experimental ALS drug.

Sep 16, 2026·4 sources
00

Novo Nordisk partners with Anthropic to use Claude AI for drug development

Novo Nordisk has partnered with Anthropic to deploy the Claude AI model to accelerate drug discovery and development processes.

Sep 16, 2026·2 sources
00
Sep 15, 2026

Axoltis Pharma reports Phase 2 failure for experimental ALS drug

French biotech Axoltis Pharma announced that its Phase 2 clinical trial for an experimental ALS treatment failed to meet its primary endpoints. The company suggested it may have found a small signal to potentially continue development.

Sep 15, 2026·1 source
00

FDA approves first radioligand equivalent, Curium's copycat of Novartis' Lutathera

The FDA has approved Curium's Bexlutry (lutetium Lu 177 dotatate injection), marking the industry's first radioligand equivalent and setting up the first generic competition for Novartis in the radioligand therapy field. The approval came after a court cleared Curium of all patent claims.

Sep 15, 2026·2 sources
00

GSK acquires Chimagen's multiple myeloma drug candidate for up to $750 million

GSK announced it will acquire a T cell engager for blood cancer from China-based Chimagen Biosciences for up to $750 million, marking its latest deal in the oncology space.

Sep 15, 2026·2 sources
00
Sep 14, 2026

Abbott settles for $385M over contaminated baby formula allegations

Abbott Laboratories agreed to pay over $384 million to settle allegations it knowingly manufactured infant formula in environments that posed substantial contamination risk, then sold the products without proper testing. Some federal prosecutors believed there was enough evidence for criminal charges, but Justice Department leadership opted for a civil settlement.

Sep 14, 2026·3 sources
00

Novo Nordisk rebrands to Novo, updates logo

Novo Nordisk announced it is shortening its corporate name to Novo and updating its logo as part of a rebranding effort amid competition in the obesity drug market.

Sep 14, 2026·2 sources
00
Sep 13, 2026

Anthropic tells investors it will be profitable for second straight quarter

AI company Anthropic has informed its backers it will be profitable this quarter, marking its second consecutive profitable quarter as it prepares for a blockbuster IPO and moves to address investor concerns about cash burn at frontier AI companies.

Sep 13, 2026·2 sources
00

GE HealthCare in talks to acquire Sofie Biosciences for $1 billion

GE HealthCare Technologies is negotiating a potential $1 billion acquisition of Sofie Biosciences, a radiopharmaceutical developer, according to reports from the Financial Times and Reuters.

Sep 13, 2026·2 sources
00

Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines

Pfizer is targeting air traffic control agencies in Poland and Romania to enforce a Belgian court ruling ordering the two countries to accept €1.9 billion worth of COVID-19 vaccines they refused to take delivery of after pandemic-era demand waned.

Sep 13, 2026·1 source
00
Sep 11, 2026

Apollo Global in talks to acquire Johnson & Johnson orthopedics unit for $20 billion

Alternative asset manager Apollo Global Management is negotiating to acquire J&J's orthopedics division in a deal valued at approximately $20 billion.

Sep 11, 2026·2 sources
00

AstraZeneca's breast cancer pill fails late-stage trial after receiving FDA approval

AstraZeneca announced that its breast cancer pill failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial. The setback came just one week after the treatment received U.S. regulatory approval.

Sep 11, 2026·4 sources
00

Diabetes leaders announce American Diabetes Association boycott after investigation of meeting ejections

A group of diabetes leaders released a letter announcing a boycott of the American Diabetes Association following the organization's independent review of ejection incidents that occurred at the ADA Scientific Sessions in June. The letter was distributed via Google Forms.

Sep 11, 2026·1 source
00
Sep 10, 2026

Takeda R&D chief Andy Plump to retire in June 2027

Andy Plump, who led Takeda's research and development overhaul and pushed the company toward biotech partnerships, will retire in June 2027 after celebrating two recent FDA approvals.

Sep 10, 2026·2 sources
00

Novartis shareholder Artisan Partners calls for board shake-up after trial setbacks

Major Novartis shareholder Artisan Partners is demanding board changes and improved dealmaking after the Swiss drugmaker's shares suffered a record fall following three consecutive major clinical trial failures, raising questions about corporate governance and R&D strategy.

Sep 10, 2026·2 sources
00
Sep 8, 2026

FDA appoints permanent leaders for drug and vaccine divisions after two years of turnover

The FDA has filled four senior roles, including naming Mikhail and Davis as permanent leaders of CBER and CDER respectively, bringing stability to the agency after nearly two years of leadership turnover under the Trump administration.

Sep 8, 2026·2 sources
00

FDA permanently appoints heads of drug and vaccine centers

The Trump administration made permanent the acting leaders of the FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), stabilizing key agency posts as a new commissioner awaits confirmation.

Sep 8, 2026·3 sources
00

Sandoz CEO warns Trump generic drug tariffs would raise costs for American patients

The CEO of Swiss pharmaceutical company Sandoz cautioned that President Donald Trump's threatened tariffs on generic drugs would ultimately be paid by American patients, as manufacturers could pass increased costs onto consumers.

Sep 8, 2026·1 source
00

Sandoz CEO warns Trump generic drug tariffs would raise costs for American patients

The CEO of Swiss pharmaceutical company Sandoz cautioned that President Donald Trump's threatened tariffs on generic drugs would ultimately be paid by American patients, as manufacturers could pass increased costs onto consumers.

Sep 8, 2026·1 source
00

AstraZeneca lung disease drug shows 30% reduction in COPD exacerbations

AstraZeneca announced its experimental drug tozorakimab achieved approximately 30% reductions in moderate and severe COPD exacerbations compared to standard therapy in two late-stage studies presented at the European Respiratory Society Congress.

Sep 8, 2026·3 sources
00

AstraZeneca's experimental COPD drug significantly reduces flare-ups in late-stage trials

AstraZeneca's experimental drug for chronic obstructive pulmonary disease significantly reduced dangerous flare-ups across a wide range of patients in two late-stage trials, positioning it as a potential blockbuster treatment for the deadly lung condition.

Sep 8, 2026·3 sources
00

AstraZeneca's experimental COPD drug shows strong results in late-stage trials

AstraZeneca released full results from two successful late-stage trials showing its experimental drug significantly reduced dangerous flare-ups in chronic obstructive pulmonary disease patients across a broad patient population, boosting the treatment's blockbuster potential.

Sep 8, 2026·8 sources
00

Bristol Myers CAR-T therapy shows high response rate in treatment-resistant blood cancer

Bristol Myers Squibb reported its experimental GPRC5D-directed CAR-T cell therapy achieved a high overall response rate in a mid-stage trial for patients with hard-to-treat multiple myeloma who had progressed after prior CAR-T treatment.

Sep 8, 2026·3 sources
00

Forus raises $150M at $3B valuation for AI drug access platform

Healthcare automation startup Forus raised $150 million in a Series C round led by Bain Capital Ventures, tripling its valuation to $3 billion in approximately four months. The company uses AI to accelerate patient access to specialty medicines.

Sep 8, 2026·4 sources
00

Novartis shares plunge 10% after experimental neuromuscular drug fails late-stage trial

Swiss pharmaceutical giant Novartis saw its stock drop as much as 10% following the failure of an experimental neuromuscular treatment in a late-stage clinical trial. The setback comes just days after another high-profile trial failure in heart disease, marking the company's third recent drug development disappointment.

Sep 8, 2026·4 sources
00

BrainChild Bio raises $116M series A for pediatric brain cancer CAR-T therapy

BrainChild Bio, spun out of Seattle Children's Hospital, secured $116 million in series A funding to advance its lead CAR-T therapy BCB-276 into pivotal trials for diffuse intrinsic pontine glioma, a rare and fatal brain tumor affecting approximately 300 U.S. children annually.

Sep 8, 2026·3 sources
00

FDA approves AstraZeneca's camizestrant for breast cancer despite advisory panel rejection

The FDA granted accelerated approval to AstraZeneca's oral SERD camizestrant (Etcamah) for breast cancer treatment, marking a rare divergence from its expert advisory panel's recommendation and opening a new ctDNA-guided treatment paradigm.

Sep 8, 2026·3 sources
00
Sep 7, 2026

FDA approves AstraZeneca's camizestrant for breast cancer despite negative advisory committee vote

The FDA granted accelerated approval to AstraZeneca's oral SERD camizestrant (Etcamah) in combination with CDK4/6 inhibitors for ESR1-mutated breast cancer, overriding a negative advisory committee recommendation.

Sep 7, 2026·2 sources
00

Novo Nordisk halts two cardiovascular trials of ziltivekimab

Novo Nordisk discontinued two additional clinical trials of its experimental cardiovascular drug ziltivekimab, further limiting the company's efforts to diversify beyond its obesity drug portfolio.

Sep 7, 2026·2 sources
00

Grindr pays £26m to settle UK lawsuit over allegedly sharing users' HIV status

Dating app Grindr has agreed to pay £26 million to settle a lawsuit brought by thousands of UK users who alleged the company shared highly sensitive personal information, including HIV status in some cases, with third parties.

Sep 7, 2026·3 sources
00

Novo Nordisk's Wegovy helps 40% of young children lose enough weight to no longer be obese in trial

In a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide (Wegovy's active ingredient) were no longer obese after treatment, compared to the control group.

Sep 7, 2026·2 sources
00
Sep 5, 2026

Novartis cholesterol drug pelacarsen fails in major clinical trial

Novartis and Ionis's pelacarsen failed to protect heart health despite lowering Lp(a) levels in a large clinical trial, raising questions about the therapeutic approach and increasing pressure on Novartis's drug pipeline. Shares fell 3.3%.

Sep 5, 2026·2 sources
00
Sep 3, 2026

Bristol Myers Squibb halts autoimmune drug trials after deaths and life-threatening side effects

Bristol Myers Squibb paused closely watched autoimmune drug research in early June after reports of life-threatening side effects and deaths, notifying regulators, researchers and patient advocacy groups.

Sep 3, 2026·2 sources
00

Ionis Pharmaceuticals wins FDA approval for first Alexander disease treatment, priced at $285,000 per dose

The FDA approved Zanvastro, an antisense oligonucleotide therapy from Ionis Pharmaceuticals, as the first targeted treatment for Alexander disease, a rare and deadly genetic neurological disorder affecting adults and children. The company priced the injectable drug at $285,000 per dose.

Sep 3, 2026·5 sources
00
Sep 1, 2026

Roche licenses tri-specific antibody from Simcere for blood cancer

Roche signed a global licensing agreement with China's Simcere for an experimental tri-specific antibody targeting blood cancers, expanding its oncology pipeline.

Sep 1, 2026·2 sources
00

Kenya signs deal with Pfizer to cut cancer drug prices by more than seven times

The Kenyan government has reached an agreement with US pharmaceutical company Pfizer that will reduce the cost of cancer medications by more than sevenfold, according to President William Ruto. The deal is expected to significantly lower treatment costs for cancer patients across the country.

Sep 1, 2026·1 source
00

Novartis pauses autoimmune cell therapy trials after three patient deaths

Novartis temporarily halted enrollment and treatment in eight clinical trials of an experimental CAR-T therapy for autoimmune and neurological disorders in late August after three patients died. Bristol Myers Squibb programs were also paused.

Sep 1, 2026·3 sources
00
Aug 31, 2026

Novartis and Bristol Myers pause autoimmune CAR-T trials due to safety concerns

Novartis has halted development of rap-cel in multiple indications and Bristol Myers voluntarily paused enrollment in autoimmune CAR-T trials after observing safety issues in testing.

Aug 31, 2026·2 sources
00
Aug 28, 2026

Walmart settles federal opioid lawsuit with Justice Department

Walmart reached a settlement with the U.S. government over allegations that the retailer fueled the nationwide opioid epidemic by unlawfully dispensing prescriptions from its pharmacies.

Aug 28, 2026·2 sources
00

Moderna raises $2.6B following major cancer vaccine trial success

Moderna completed an upsized note offering to support its cancer work shortly after achieving a significant win in a crucial clinical study of its mRNA cancer vaccine developed with Merck.

Aug 28, 2026·2 sources
00

Cytokinetics reports positive late-stage data for heart drug aficamten

Cytokinetics announced detailed late-stage trial results showing its drug aficamten significantly improved symptoms and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy, a genetic heart condition with no approved treatments.

Aug 28, 2026·2 sources
00
Aug 27, 2026

Meta reaches settlement with US states over teen mental health protections on Instagram and Facebook

Meta agreed to implement changes for minors on Instagram and Facebook, including cutting off access at night and during school hours. However, a whistleblower criticized the settlement as insufficient to meaningfully address harms to teen mental health.

Aug 27, 2026·2 sources
00

AstraZeneca and Amgen's Tezspire meets Phase 3 goals in eosinophilic esophagitis

Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, potentially becoming the drug's third approved indication and positioning it to compete with Sanofi's Dupixent, currently the only approved biologic for the condition.

Aug 27, 2026·2 sources
00
Aug 26, 2026

White House to announce new drug pricing deals with biotech companies

The Trump administration plans to announce a new round of drug-pricing agreements with several midsized biotech companies on Monday, according to people familiar with the matter.

Aug 26, 2026·2 sources
00

Biohaven licenses epilepsy drug platform to SK Biopharmaceuticals for up to $795 million

Biohaven Pharmaceuticals has entered into a licensing agreement with South Korean drugmaker SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, in a deal worth up to $795 million.

Aug 26, 2026·2 sources
00
Aug 25, 2026

McKesson acquires Precision Medicine Group for $2.25 billion

Drug distributor McKesson agreed to buy privately held Precision Medicine Group in a $2.25 billion deal, continuing its multi-year strategy to strengthen higher-growth clinical research capabilities.

Aug 25, 2026·2 sources
00
Aug 24, 2026

Pharmacy error at Ascension Nashville hospital injures four joint replacement patients

Four patients at an Ascension hospital in Nashville were injected with potassium phosphate instead of spinal anesthetic due to a pharmacy mix-up, with one patient paralyzed and three others harmed.

Aug 24, 2026·2 sources
00

Bristol Myers ends blood cancer drug partnership with Cellares

Bristol Myers Squibb terminated its partnership with cell therapy startup Cellares to expand manufacturing of its personalized blood cancer therapy, prompting Cellares to lay off 100 employees.

Aug 24, 2026·2 sources
00

Roche gains rights to Hanmi obesity drug that preserves muscle mass

Roche acquired rights to Hanmi Pharmaceutical's obesity drug for $190 million upfront and up to $2.3 billion total. The drug is designed to activate receptors in skeletal muscle to increase muscle mass while reducing fat, addressing a key concern with current GLP-1 weight loss medications.

Aug 24, 2026·2 sources
00

FDA clears Roche and Eli Lilly's blood test for Alzheimer's disease detection

The FDA has cleared a blood test developed by Roche and Eli Lilly to help identify signs of Alzheimer's disease in people aged 55 and older with cognitive decline.

Aug 24, 2026·3 sources
00
Aug 20, 2026

Abbott Laboratories to pay $670 million to settle preterm infant formula lawsuits

Abbott agreed to pay $670 million to settle lawsuits alleging it concealed risks that its preterm infant formula can cause necrotizing enterocolitis, a deadly bowel disease in premature babies.

Aug 20, 2026·2 sources
00
Aug 19, 2026

Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence in late-stage trial

Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.

Aug 19, 2026·6 sources
00
Aug 18, 2026

Amylyx drug avexitide reduces severe low blood sugar episodes in post-bariatric surgery patients

Amylyx Pharmaceuticals' experimental drug avexitide met its primary endpoint in a Phase 3 trial for post-bariatric hypoglycemia, showing a 55% reduction in serious low blood sugar events compared to placebo in patients who experienced dangerously low blood sugar following weight-loss surgery.

Aug 18, 2026·2 sources
00

Leo Pharma acquires worldwide rights to dersimelagon for up to $435M

Danish drugmaker Leo Pharma agreed to acquire worldwide rights to dersimelagon, a late-stage drug candidate for two rare genetic skin diseases, from Tanabe Pharma for up to $435 million in upfront and milestone payments.

Aug 18, 2026·2 sources
00
Aug 17, 2026

Fulcrum Therapeutics to merge with Slate Medicines in reverse merger with $245M financing

Fulcrum Therapeutics announced an all-stock reverse merger with privately held Slate Medicines, accompanied by a $245 million private placement. The deal follows Fulcrum's discontinuation of its lead drug development after regulatory setbacks.

Aug 17, 2026·3 sources
00

UnitedHealth faces IRS probe over potential tax avoidance through foreign subsidiary

The IRS is investigating UnitedHealth over potential tax avoidance related to transfers to a foreign subsidiary, seeking to recoup taxes. This adds to mounting scrutiny following the Change Healthcare cyberattack and investor lawsuits alleging governance failures.

Aug 17, 2026·3 sources
00

AstraZeneca halts late-stage lung cancer trial of volrustomig after interim analysis shows unlikely success

AstraZeneca discontinued a Phase 3 trial combining its experimental bispecific antibody volrustomig with chemotherapy for lung cancer after an interim data review indicated survival goals would likely not be met. This marks another setback for the company's pipeline as it pursues an $80 billion sales target.

Aug 17, 2026·3 sources
00
Aug 14, 2026

FDA approves Bristol Myers Squibb's Zenbexus, first CELMoD drug for multiple myeloma

The FDA has approved Zenbexus (iberdomide) for multiple myeloma treatment, marking the first approval in the novel CELMoD drug class that uses targeted protein degradation. Bristol Myers Squibb acquired the therapy through its Celgene acquisition and is positioning it as a successor to its legacy myeloma products.

Aug 14, 2026·4 sources
00
Aug 13, 2026

Grifols pauses plasma collection at Canadian clinics after two donor deaths

Spanish pharmaceutical company Grifols has temporarily halted plasma donations at all 16 of its Canadian clinics following the deaths of two donors and a government investigation into potential unsafe practices at the for-profit facilities.

Aug 13, 2026·3 sources
00

PTC Therapeutics acquires Sangamo's Fabry disease gene therapy for $211M in bankruptcy auction

PTC Therapeutics won the bankruptcy auction for Sangamo Therapeutics' gene therapy assets with a $211 million bid. Sangamo filed for Chapter 11 bankruptcy in June after failing to find strategic alternatives.

Aug 13, 2026·2 sources
00
Aug 12, 2026

Luigi Mangione pleads guilty to federal charges in UnitedHealthcare CEO killing

Luigi Mangione pleaded guilty to federal stalking charges in the killing of UnitedHealthcare CEO Brian Thompson, admitting he trailed the executive to an investor conference before shooting him in December 2024.

Aug 12, 2026·3 sources
00

Boulevard Bio launches with $65M to develop targeted autoimmune antibodies

Deerfield Management formed Boulevard Bio with renowned autoimmune researchers Georg Schett and Frank Nestle, raising $65 million to advance a trio of multifaceted antibodies for immune diseases.

Aug 12, 2026·3 sources
00

Eli Lilly escalates legal fight against black market for experimental weight-loss drug retatrutide

Eli Lilly is stepping up legal action against a booming black market for retatrutide, an experimental weight-loss drug the company is counting on to expand its franchise beyond approved medications like Zepbound.

Aug 12, 2026·2 sources
00

Prader-Willi syndrome experts raise safety concerns over Neurocrine's Vykat XR

Medical experts specializing in Prader-Willi syndrome flagged serious adverse events in patients taking Neurocrine Biosciences' drug Vykat XR, raising safety concerns about the treatment for the rare genetic disorder.

Aug 12, 2026·2 sources
00

Boulevard Bio launches with $65M to develop targeted autoimmune antibody therapies

Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.

Aug 12, 2026·4 sources
00
Aug 11, 2026

Cardinal Health raises full-year profit forecast on specialty drug strength

U.S. drug distributor Cardinal Health forecast fiscal 2027 profit well above Wall Street expectations after beating fourth-quarter estimates, driven by sustained demand for specialty drugs.

Aug 11, 2026·2 sources
00
Aug 10, 2026

Hims & Hers posts wider loss as shift to branded weight-loss drugs drives up costs

Hims & Hers Health reported a wider-than-expected second-quarter loss as the telehealth company's shift to branded weight-loss drugs drove up costs, sending shares down 6% in extended trading. The company plans to enter the peptides market before year-end.

Aug 10, 2026·3 sources
00

Novo Nordisk and Amazon Web Services Launch AI Co-Innovation Hub in London for Drug Discovery

Novo Nordisk and Amazon Web Services have formed a strategic partnership to accelerate drug discovery through artificial intelligence, establishing a new AI co-innovation hub in London that will bring together AWS engineers and AI specialists with Novo Nordisk's research and development teams.

Aug 10, 2026·3 sources
00

Sobi and Innate Pharma Form $580M Partnership to Advance Lacutamab to Phase 3 for Rare Skin Cancer

Swedish Orphan Biovitrum (Sobi) and Innate Pharma announced a strategic partnership worth up to $580 million, with $75 million upfront, to advance lacutamab into the TELLOMAK-3 Phase 3 confirmatory trial for cutaneous T-cell lymphoma, specifically Sézary syndrome. Innate Pharma also appointed Markus Jensen as Chief Medical Officer.

Aug 10, 2026·9 sources
00

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to $1.32 Billion in Rare Epilepsy Deal

Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments, gaining access to ABS-1230, an experimental treatment for KCNT1+ epilepsy, a rare inherited form of the disease with no approved therapies.

Aug 10, 2026·6 sources
00

UK becomes first European country to approve Eli Lilly's once-daily weight loss pill Foundayo

The UK's Medicines and Healthcare products Regulatory Agency has authorized orforglipron (brand name Foundayo), a once-daily oral medication from Eli Lilly for treating obesity and type 2 diabetes, making the UK the first country in Europe to approve the drug.

Aug 10, 2026·6 sources
00
Aug 7, 2026

Scholar Rock Removes Novo Nordisk Indiana Facility from FDA Application for Rare Muscle Weakness Drug

Scholar Rock announced it will remove Novo Nordisk's (formerly Catalent's) Indiana manufacturing facility from its FDA biologics license application for a treatment targeting a rare neuromuscular disease. The regulatory filing adjustment comes as the company seeks approval for its muscle weakness therapy.

Aug 7, 2026·5 sources
00

BlossomHill Therapeutics raises $150 million in upsized oncology IPO

Oncology-focused biotech firm BlossomHill Therapeutics raised $150 million in an upsized U.S. initial public offering, though shares fell 1.6% in their trading debut.

Aug 7, 2026·2 sources
00
Aug 6, 2026

Amazon Pharmacy begins offering GLP-1 weight loss drugs to Medicare patients

Amazon announced that Medicare Part D patients can now access certain GLP-1 weight-loss medications including oral and injectable versions of Novo Nordisk's drugs through Amazon Pharmacy.

Aug 6, 2026·2 sources
00

Tarsus Pharmaceuticals to Acquire Alkeus for Up to $800M, Gaining Late-Stage Stargardt Disease Drug

Tarsus Pharmaceuticals agreed to acquire privately-held Alkeus Pharmaceuticals for $450 million upfront and up to $800 million total, gaining gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease. The rare genetic eye condition affects over 36,000 people in the U.S. and currently has no FDA-approved treatment, with pivotal trial data expected in late 2029.

Aug 6, 2026·5 sources
00

KKR Acquires Medicover India's 24-Hospital Network for $1.3 Billion

Global investment firm KKR has signed a definitive agreement to acquire Medicover India, the Indian hospital business of Stockholm-based Medicover, in a deal valued at approximately $1.3 billion (₹10,000-14,250 crore). The acquisition marks KKR's largest healthcare deal in India and includes a 24-hospital network, with plans for additional investment of ₹3,000-4,000 crore for expansion.

Aug 6, 2026·7 sources
00
Aug 5, 2026

FDA approves Takeda's Orzeyful, first orexin agonist drug for narcolepsy type 1

The FDA has approved Takeda's Orzeyful (orexin agonist) for treating narcolepsy type 1 in adults, marking the first approval in a new class of sleep medicines that addresses the full range of narcolepsy symptoms. The approval is expected to reshape the treatment paradigm and launch a closely watched commercial drug race.

Aug 5, 2026·5 sources
00
Aug 4, 2026

Biotech Startup Abandons Plans to Scale Custom CRISPR Therapies

A startup that had promised to commercialize and scale personalized CRISPR gene-editing therapies has abruptly canceled its plans, marking a setback for the custom therapeutics sector.

Aug 4, 2026·1 source
00

Novo Nordisk shares slide despite beating quarterly estimates

Novo Nordisk reported quarterly results that beat expectations and raised guidance, but shares fell as investors remained concerned about the company's path to sustainable growth amid increasing competition in the obesity drug market.

Aug 4, 2026·2 sources
00

Procter & Gamble acquires supplement maker Thorne for $3.8 billion

P&G won the bidding war for supplement brand Thorne in a deal valued at $3.8 billion, marking a major push into the health and wellness sector.

Aug 4, 2026·2 sources
00

Pfizer beats revenue estimates on strength of Eliquis and other drugs

Pfizer reported second-quarter revenue that exceeded analyst expectations, driven by strong sales of blood thinner Eliquis and other key medications. The company raised the low end of its full-year revenue guidance.

Aug 4, 2026·1 source
00

Merck's anti-TL1A antibody shows mixed Phase 2 results in hidradenitis suppurativa and lung disease

Merck's anti-TL1A antibody from its 2023 Prometheus Biosciences acquisition delivered positive mid-stage results in hidradenitis suppurativa but failed to meet endpoints in a rare lung disease trial. The company disclosed the mixed Phase 2 results alongside its second-quarter earnings.

Aug 4, 2026·2 sources
00

Merck raises 2026 sales outlook on strength of newer drugs including Winrevair

Merck beat second-quarter estimates and boosted its 2026 sales forecast after strong demand for newer drugs like Winrevair helped drive revenues higher, though the company cut profit guidance due to deal-related charges.

Aug 4, 2026·2 sources
00
Aug 3, 2026

TikTok Settles Three Teen Addiction Lawsuits Ahead of Trial, Thousands More Cases Pending

TikTok has agreed to settle three lawsuits brought by teenagers alleging the platform was designed to be addictive and caused mental health harm, with settlements finalized ahead of planned October trials. The cases are part of approximately 3,300 lawsuits against major social media companies including Meta, Google, and Snap.

Aug 3, 2026·8 sources
00

Eli Lilly Opens Limited Early Access Program for Experimental Obesity Drug Retatrutide

Pharmaceutical company Eli Lilly announced it will allow a limited number of patients with severe obesity to access its unapproved experimental drug retatrutide through a compassionate use program, following a case where it granted the drug to a 79-year-old patient. The program has strict eligibility criteria that most patients cannot meet.

Aug 3, 2026·7 sources
00

California Supreme Court rules drugmakers have no 'duty to innovate' safer products in Gilead Sciences case

California's highest court ruled Monday that pharmaceutical manufacturers of drugs deemed safe are not legally obligated to develop safer alternatives, delivering a victory to Gilead Sciences in a closely watched case that could have broad implications for the pharmaceutical industry.

Aug 3, 2026·4 sources
00

Sandoz to pay $478.5 million to settle price-fixing allegations

Sandoz agreed to pay $478.5 million to settle long-running price-fixing allegations with multiple U.S. states in a major pharmaceutical antitrust case.

Aug 3, 2026·1 source
00

Curium to take radiopharma company Lantheus private in $8 billion deal

Nuclear medicine company Curium has struck a deal to take Lantheus Holdings Inc. private in a transaction worth approximately $8 billion.

Aug 3, 2026·2 sources
00

Supernus Pharmaceuticals and Indivior Pharmaceuticals Agree to All-Stock Merger Creating $2.2 Billion CNS Drug Company

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced an all-stock merger to create a combined company with approximately $2.2 billion in annual revenue and a portfolio of 11 commercialized medicines focused on neurological, psychiatric, and addiction-related conditions. The deal, described as a merger of equals, is expected to generate $125 million in cost savings.

Aug 3, 2026·9 sources
00

Sandoz agrees to $450 million settlement with 43 US states over generic drug price-fixing allegations

Swiss generic drugmaker Sandoz has reached a settlement agreement to pay $450 million to 43 US states and territories to resolve antitrust litigation alleging anti-competitive conduct and price manipulation in the generic medicines market. The settlement includes no admission of wrongdoing and will not affect the company's financial guidance.

Aug 3, 2026·9 sources
00
Aug 2, 2026

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal

AstraZeneca is reportedly in discussions with Bristol Myers Squibb regarding a potential $400 billion merger, which would create one of the largest pharmaceutical companies globally and reshape the cancer treatment industry.

Aug 2, 2026·1 source
00

Michigan Supreme Court Clears Path for Attorney General's Investigation into Eli Lilly Insulin Pricing

The Michigan Supreme Court ruled 4-3 on July 31, 2026, overturning two lower court decisions and allowing Attorney General Dana Nessel to proceed with an investigation into Eli Lilly's insulin pricing practices under the Michigan Consumer Protection Act.

Aug 2, 2026·6 sources
00
Jul 31, 2026

Novo Nordisk's experimental drug fails to reduce heart attacks and strokes in large study

Novo Nordisk's experimental inflammation-targeting drug failed to reduce the risk of heart attacks and strokes in a closely watched large clinical trial, a setback for the drugmaker's growth prospects beyond obesity and diabetes.

Jul 31, 2026·2 sources
00
Jul 30, 2026

Johnson & Johnson secures option to acquire CAR-T biotech Sail Biomedicines for $2.6 billion

J&J has obtained an option to purchase Sail Biomedicines, a Flagship Pioneering-backed startup developing 'in vivo' CAR-T therapies, in a deal valued at nearly $2.6 billion.

Jul 30, 2026·1 source
00

Merck-Wellcome Joint Venture to Manufacture Experimental Ebola Vaccine for Congo Outbreak

Hilleman Laboratories, a Singapore-based partnership between Merck and Wellcome, is preparing to produce doses of an experimental vaccine targeting the rare Bundibugyo strain of Ebola amid a fast-spreading outbreak in the Democratic Republic of Congo.

Jul 30, 2026·1 source
00
Jul 29, 2026

Latigo reports positive mid-stage trial results for pain drug competing with Vertex's Journavx

Latigo has announced successful mid-stage clinical trial results for its non-opioid pain medication, positioning it as a potential competitor to Vertex Pharmaceuticals' pain drug Journavx in a field historically marked by development failures.

Jul 29, 2026·1 source
00

FTC sues Hims & Hers over sharing users' health information with advertisers

The Federal Trade Commission, Utah, and Los Angeles County sued telehealth company Hims & Hers Health for allegedly misleading consumers about its products and sharing private health information with advertisers. Shares fell 10% following the announcement.

Jul 29, 2026·2 sources
00
Jul 28, 2026

GSK partner Hansoh Pharmaceutical's bone cancer drug meets primary endpoint in second Phase III trial in China

Hansoh Pharmaceutical announced positive results from the ARTEMIS-011 Phase III trial in China, with its experimental drug Ris-Rez meeting the primary endpoint of progression-free survival in relapsed bone cancer patients. This marks the second Phase III success for the drug, strengthening GSK's oncology portfolio through its licensing partnership with the Chinese biotech.

Jul 28, 2026·3 sources
00
Jul 27, 2026

Chinese Drugmaker Innocare Reports Positive Late-Stage Trial Results for Psoriasis Oral Treatment

Innocare Pharma announced its experimental oral drug for moderate-to-severe plaque psoriasis showed consistent treatment effects in late-stage clinical trials, entering a competitive market where recent head-to-head studies have compared efficacy of various psoriasis treatments.

Jul 27, 2026·3 sources
00

Sarepta Therapeutics appoints Michael Severino as new CEO

Sarepta Therapeutics named former AbbVie executive Michael Severino as its new chief executive officer as the company seeks to recover from declining share prices and faces looming competition in its rare disease drug portfolio.

Jul 27, 2026·2 sources
00

ICMR licenses cervical cancer drug SHetA2 to Emcure Pharmaceuticals for development in India

India's ICMR has licensed SHetA2, an experimental drug that aims to prevent HPV from turning cancerous, to Emcure Pharmaceuticals for development. The move addresses India's significant cervical cancer burden, with approximately 123,907 new cases and 77,348 deaths annually.

Jul 27, 2026·3 sources
00

AstraZeneca's Sonesitatug Vedotin Shows Significant Survival Improvement in Phase III Gastric Cancer Trial

Phase III CLARITY-Gastric01 trial results showed sonesitatug vedotin (Sone-Ve) achieved statistically significant overall survival improvement in CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma patients in second-line and later settings, meeting its dual primary and key secondary endpoints.

Jul 27, 2026·4 sources
00

Argenx to Acquire Forte Biosciences for $2.2 Billion to Expand Immunology Portfolio

Belgian-Dutch biotech argenx agreed to acquire Forte Biosciences for $2.2 billion in cash ($77 per share, an 86% premium to its VWAP since July 9), adding FB102, an anti-CD122 antibody in development for vitiligo and celiac disease, to its immunology pipeline.

Jul 27, 2026·4 sources
00
Jul 24, 2026

Merck licenses experimental once-monthly HIV pill to seven generic manufacturers for 129 countries

Merck signed voluntary licensing agreements with seven generic drug manufacturers—including Aspen Pharmacare, Cipla, Aurobindo, and Viatris—to produce and sell lower-cost versions of alimatravir, its experimental once-monthly oral HIV pill, in 129 low- and middle-income countries. The drug is currently in late-stage development.

Jul 24, 2026·6 sources
00
Jul 23, 2026

Eli Lilly's retatrutide shows positive Phase 3 results, plans Q1 2027 FDA application

Eli Lilly announced positive results from two additional Phase 3 trials of its experimental obesity drug retatrutide (a 'triple-G' GLP-1 receptor agonist), showing it did not increase overall heart risk. The company plans to submit an FDA application in Q1 2027.

Jul 23, 2026·3 sources
00

European Commission Approves AstraZeneca's Etcamah for ER-Positive Breast Cancer with ESR1 Mutations

The European Commission has approved AstraZeneca's Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for first-line treatment of adults with ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. The approval is based on SERENA-6 Phase III trial results showing a 56% reduction in risk of disease progression or death.

Jul 23, 2026·9 sources
00
Jul 22, 2026

Johnson & Johnson receives FDA approval for soft tissue surgical robot

After more than a decade of development, J&J's robotic surgery device received FDA marketing authorization, allowing the healthcare conglomerate to enter the competitive surgical robotics market.

Jul 22, 2026·2 sources
00

Repligen acquires BioLife Solutions in $1.5 billion deal to expand cell therapy business

Repligen Corp announced it will acquire BioLife Solutions in a cash-and-stock transaction valued at approximately $1.5 billion. The deal expands Repligen's presence in the fast-growing cell therapy market.

Jul 22, 2026·1 source
00
Jul 21, 2026

Garmin Launches CIRQA Screenless Fitness Band to Challenge Whoop

Garmin Ltd. has officially released the Cirqa Smart Band, a screenless fitness tracker priced at $200 (£180, S$258) that directly competes with Whoop Inc. but does not require a subscription. The device focuses on health and fitness tracking through a display-free design.

Jul 21, 2026·6 sources
00

Gilead Sciences and Merck's Once-Weekly HIV Pill Maintains Viral Suppression in Phase 3 Trials

Gilead Sciences and Merck announced that their experimental once-weekly HIV pill combining islatravir and lenacapavir successfully maintained viral suppression at 48 weeks in two Phase 3 trials (ISLEND-1 and ISLEND-2) involving 1,209 adults with virologically suppressed HIV. The results support regulatory filings for what could become the first once-weekly oral HIV treatment regimen.

Jul 21, 2026·7 sources
00
Jul 20, 2026

Takeda's QDENGA becomes first dengue vaccine approved in India

Japan's Takeda Pharmaceutical received approval from India's drug regulator for QDENGA, marking the first dengue vaccine to be approved in the country.

Jul 20, 2026·1 source
00

Samsung Biologics to Acquire Swiss Drugmaker PolyPeptide for $1.8 Billion in All-Cash Deal

Samsung Biologics announced an all-cash tender offer to acquire Switzerland's PolyPeptide Group AG for CHF 1.46 billion ($1.8B), at CHF 44.31 per share — a 6.1% premium to last close and ~40% to the April 10, 2026 undisturbed price, marking South Korea's largest biopharma acquisition.

Jul 20, 2026·6 sources
00
Jul 16, 2026

Serum Institute of India to Manufacture Experimental TB Vaccine M72/AS01E in Partnership with Gates Medical Research Institute

The Serum Institute of India has signed an agreement with the Gates Medical Research Institute to manufacture M72/AS01E, a novel tuberculosis vaccine candidate currently in late-stage clinical trials. If approved, it would be the first new TB vaccine in over 100 years, with Serum Institute planning to invest over $100 million in production.

Jul 16, 2026·3 sources
00

Merck wins FDA approval for first oral PCSK9 cholesterol pill

Merck received FDA approval for its oral PCSK9 inhibitor cholesterol pill, the first of its kind, offering a more convenient alternative to existing injectable therapies for high-risk patients.

Jul 16, 2026·4 sources
00

UnitedHealth raises annual profit forecast as medical costs stabilize

UnitedHealth Group raised its 2026 profit outlook and beat quarterly earnings estimates, signaling recovery from previous challenges through tighter management of medical costs and improved performance in its Optum health services business.

Jul 16, 2026·4 sources
00
Jul 15, 2026

Eli Lilly nears deal to acquire psychedelic drugmaker AtaiBeckley

Eli Lilly is in advanced talks to acquire AtaiBeckley, a psychedelic medicine company, with a deal potentially announced this week. The acquisition underscores growing interest from major pharmaceutical companies in psychedelic therapies.

Jul 15, 2026·2 sources
00

Novo Nordisk Receives EU Approval for First Oral GLP-1 Weight-Loss Treatment

The European Commission has approved Novo Nordisk's once-daily Wegovy pill for weight management in adults with obesity or who are overweight, marking the first oral GLP-1 weight-loss treatment cleared for use across the European Union.

Jul 15, 2026·2 sources
00

Johnson & Johnson beats earnings estimates on strength of Tremfya and Darzalex

Johnson & Johnson exceeded Wall Street estimates for second-quarter sales and profit, driven by strong demand for immunology drug Tremfya and cancer treatment Darzalex, offsetting erosion in other product lines.

Jul 15, 2026·1 source
00

Neko Health raises $700 million ahead of US launch

Stockholm-based Neko Health, a technology firm focused on disease prevention and early detection, raised $700 million in Series C funding as it prepares to launch operations in the United States.

Jul 15, 2026·1 source
00
Jul 14, 2026

HCA Healthcare Cuts Annual Profit Forecast as Obamacare Coverage Losses Increase Uninsured Patient Load

HCA Healthcare lowered its annual profit forecast on Tuesday, citing a rise in uninsured patients and increased uncompensated care costs driven largely by Americans dropping coverage under Affordable Care Act (Obamacare) plans.

Jul 14, 2026·3 sources
00

AstraZeneca Acquires Lung Cancer Drug from China's Dizal Pharmaceutical in $1.5 Billion Deal

AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to a lung cancer drug, with total deal value reaching $1.5 billion including milestone payments. The drug is commercial-ready and adds to AstraZeneca's oncology franchise.

Jul 14, 2026·2 sources
00
Jul 10, 2026

Warburg Pincus Nears $7 Billion Acquisition of Specialty Pharmacy PANTHERx Rare

Private equity firm Warburg Pincus is close to acquiring specialty pharmacy company PANTHERx Rare for more than $7 billion including debt, according to the Wall Street Journal.

Jul 10, 2026·1 source
00
Jul 9, 2026

AstraZeneca and Ionis' heart disease drug Wainua fails pivotal trial, shares plunge

AstraZeneca's shares fell as much as 9% after Wainua, a drug developed with Ionis Pharmaceuticals, unexpectedly failed to meet its primary endpoint in a late-stage trial for ATTR-CM heart disease. The failure has raised concerns about the company's trial design and shaken investor confidence.

Jul 9, 2026·4 sources
00
Jul 8, 2026

FDA approves Johnson & Johnson's dual-energy cardiac ablation catheter combining radiofrequency and pulsed field technology

The FDA has approved J&J's ThermoCool SmartTouch SF Platform, allowing electrophysiologists to switch between radiofrequency and pulsed field energy through a single catheter integrated with the Carto mapping system. U.S. physicians are expected to begin using the device this summer.

Jul 8, 2026·4 sources
00

AstraZeneca and Daiichi Sankyo Near UK Pricing Agreement for Breast Cancer Drug Enhertu

AstraZeneca and Daiichi Sankyo are nearing a pricing agreement with the UK's National Institute for Health and Care Excellence (NICE) for their breast cancer treatment Enhertu, which could provide access to women in England and Wales with HER2-low breast cancer.

Jul 8, 2026·2 sources
00
Jul 6, 2026

Vertex Pharmaceuticals to Acquire Crinetics for $10 Billion in Largest Deal Ever

Vertex Pharmaceuticals agreed to buy Crinetics Pharmaceuticals for approximately $10 billion in cash, marking Vertex's largest acquisition to date and expanding its portfolio into rare hormonal and endocrinology diseases.

Jul 6, 2026·3 sources
00

Novartis to Acquire UK Biotech Myricx Bio for Up to $1.5 Billion

Swiss pharmaceutical company Novartis has agreed to acquire UK-based biotechnology firm Myricx Bio for up to $1.5 billion, gaining access to experimental antibody-drug conjugates (ADCs) designed to deliver cancer treatments directly to tumors. The deal is expected to close in the second half of 2026.

Jul 6, 2026·3 sources
00
Jul 2, 2026

Roche's divarasib outperforms Amgen and Bristol Myers Squibb drugs in Phase 3 lung cancer trial

Roche announced positive results from a head-to-head Phase 3 trial showing its KRAS G12C inhibitor divarasib demonstrated superior efficacy compared to competing treatments from Amgen and Bristol Myers Squibb in patients with KRAS-driven lung cancer.

Jul 2, 2026·4 sources
00
Jun 29, 2026

FDA peptide advisory panel to include doctors and pharmacists with financial ties to unproven peptide industry

U.S. health officials have appointed doctors and pharmacists with deep financial connections to the peptide industry to an FDA advisory panel that will reconsider controversial peptide drugs next month. The appointments raise ethics concerns given the panelists could benefit from regulatory changes they help shape.

Jun 29, 2026·5 sources
00

FDA Selects Eli Lilly and Regeneron for Pilot Program to Accelerate Manufacturing Facility Reviews

The FDA selected seven companies including Eli Lilly and Regeneron for a pilot program designed to speed up reviews of new domestic pharmaceutical manufacturing facilities, aiming to strengthen U.S. drug supply chains.

Jun 29, 2026·2 sources
00

Zymeworks Acquires Theravance Biopharma for $929 Million to Expand Beyond Cancer

Cancer-focused drugmaker Zymeworks will acquire Theravance Biopharma for $929 million in cash, marking its entry into the respiratory disease segment and expanding beyond its oncology focus.

Jun 29, 2026·2 sources
00

Roche Launches Axelios Gene Sequencer to Challenge Illumina's Market Dominance

Swiss pharmaceutical giant Roche launched its long-awaited Axelios gene sequencer, aiming to break Illumina's leadership position in the next-generation sequencing market.

Jun 29, 2026·1 source
00

Pfizer and Innovent Biologics GLP-1 Drugs Pass Preliminary Review for China Insurance Coverage

GLP-1 drugs from Pfizer and Innovent Biologics have cleared preliminary review to potentially be included in China's basic medical insurance drug catalogue, which would expand access to these treatments.

Jun 29, 2026·1 source
00
Jun 27, 2026

States target pharmacy benefit managers in effort to lower prescription drug prices

Multiple U.S. states are implementing measures to regulate pharmacy benefit management companies that oversee prescription drug coverage for health insurers, as part of efforts to reduce medication costs for consumers.

Jun 27, 2026·2 sources
00
Jun 26, 2026

Biogen Scales Back Apellis Programs and Cuts Research Roles Following $5.6 Billion Acquisition

Biogen has paused or discontinued funding for most of Apellis Pharmaceuticals' research programs and is trimming research positions as it integrates the rare-disease drugmaker it acquired for $5.6 billion.

Jun 26, 2026·1 source
00

Elevance Health Pays $342 Million to Settle Medicare Advantage Overbilling Allegations

Elevance Health has paid the federal government more than $342 million to settle allegations that it overcharged Medicare Advantage for years. The payment comes amid an ongoing billing probe into the major insurer, which covers approximately 2 million Medicare Advantage beneficiaries.

Jun 26, 2026·2 sources
00
Jun 24, 2026

ALZpath Signs Global Licensing Agreement with Abbott Laboratories for Alzheimer's Blood Test Development

ALZpath announced a global licensing deal with Abbott Laboratories to advance blood-based testing for Alzheimer's disease, joining the race to develop easier-to-use diagnostic options for the neurodegenerative condition.

Jun 24, 2026·1 source
00

Ollin Biosciences Raises $330 Million for Late-Stage Eye Disease Drug Trials

Texas-based biotech Ollin Biosciences secured $330 million in funding to advance late-stage clinical studies of its experimental eye disease treatment, representing one of the largest recent funding rounds in ophthalmology.

Jun 24, 2026·2 sources
00
Jun 23, 2026

Eli Lilly Grants Compassionate Use Access to Experimental Obesity Drug Retatrutide for Single Patient

Eli Lilly provided its experimental 'triple-G' weight loss drug retatrutide to a 79-year-old patient through the FDA's compassionate use program, marking an extremely rare instance of pre-approval access to an obesity medication.

Jun 23, 2026·2 sources
00
Jun 20, 2026

Sun Pharma Acquires Innovcare Lifesciences for $28.7 Million

Indian pharmaceutical company Sun Pharma announced the acquisition of Innovcare Lifesciences for $28.7 million, expanding its portfolio in the specialty pharmaceutical sector.

Jun 20, 2026·1 source
00
Jun 9, 2026

GSK Acquires Nuvalent for $10.6 Billion to Expand Cancer Drug Portfolio

UK pharmaceutical giant GSK has entered an agreement to acquire U.S.-based cancer drugmaker Nuvalent for $10.6 billion, adding targeted cancer therapies to its portfolio in one of the year's largest biopharma acquisitions.

Jun 9, 2026·3 sources
00
Jun 8, 2026

Roche enters licensing deal with Nurix Therapeutics for blood cancer drug worth up to $2.3-3 billion

Swiss pharmaceutical giant Roche has signed an exclusive licensing and collaboration agreement with Nurix Therapeutics for bexobrutinib, a protein degrader drug targeting B cell malignancies and blood cancers. The deal value is reported as up to $2.3 billion by one source and up to $3 billion by another.

Jun 8, 2026·2 sources
00

Zealand Pharma Shares Plunge 25% After Safety Data Raises Concerns Over Experimental Weight Loss Drug

Shares of Danish drugmaker Zealand Pharma dropped as much as 26% after new safety data on its experimental obesity medicine raised investor concerns over potential side effects.

Jun 8, 2026·1 source
00

AstraZeneca's experimental obesity pill achieves 10.5% weight loss in phase II trial

AstraZeneca announced results from a phase II trial showing its oral GLP-1 therapy reduced body weight by 10.5%, positioning the company to compete with Eli Lilly in the race to develop convenient pill-based obesity treatments. The drug is advancing to late-stage trials.

Jun 8, 2026·2 sources
00
Jun 2, 2026

NewLimit Raises $435 Million Series C Ahead of First Clinical Trial for Longevity Medicine

Longevity-focused biotech startup NewLimit announced a $435 million Series C funding round as it prepares to launch its first clinical trial of a liver medicine, marking one of the largest recent raises in the longevity space.

Jun 2, 2026·1 source
00

Abivax Shares Plunge Over 30% as Cancer Cases Overshadow Inflammatory Bowel Disease Trial Results

French biotech Abivax saw its stock tumble over 30% after reporting late-stage trial data for its ulcerative colitis drug, with investors focusing on safety concerns related to cancer cases despite the treatment showing efficacy.

Jun 2, 2026·2 sources
00
Jun 1, 2026

Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business for Up to $2.65 Billion

French pharmaceutical company Servier will acquire Edgewise Therapeutics' experimental muscular dystrophy drug and related business for up to $2.65 billion. Edgewise will pivot to focus on cardiovascular drugs following the transaction.

Jun 1, 2026·2 sources
00
May 31, 2026

Johnson & Johnson's Prostate Cancer Drug Reduces Risk of Cancer Spread and Death in Late-Stage Study

J&J's Erleada used with hormone-blocking therapy six months before and after prostate surgery improved cancer elimination rates and reduced the risk of cancer spread and death in a late-stage trial for prostate cancer patients.

May 31, 2026·2 sources
00

Novartis Experimental Radiopharma Drug Shows Anti-Tumor Activity in Early Prostate Cancer Study

Novartis reported early data showing its experimental actinium-based radiopharma drug demonstrated anti-tumor activity against prostate cancer, including in patients previously treated with its older therapies.

May 31, 2026·1 source
00
May 30, 2026

Mineralys Therapeutics' Experimental Drug Significantly Reduces Blood Pressure in Chronic Kidney Disease Patients

Mineralys Therapeutics presented new data at a major European medical conference showing their experimental pill significantly reduced blood pressure in patients with chronic kidney disease.

May 30, 2026·1 source
00
May 29, 2026

Bristol Myers Squibb's Mezigdomide Delays Disease Progression in Late-Stage Multiple Myeloma Trial

Bristol Myers Squibb announced its experimental oral drug mezigdomide successfully delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed or not responded to prior treatments.

May 29, 2026·1 source
00

Agios Pharmaceuticals Discontinues Blood Cancer Drug Program After Mid-Stage Trial Failure

Agios Pharmaceuticals announced it will stop developing its experimental drug for a form of blood cancer after a mid-stage trial failed to show sufficient benefit, marking a setback for the rare disease program.

May 29, 2026·1 source
00
May 28, 2026

CVS Health Restores Coverage of Eli Lilly's Zepbound and Adds New Obesity Pill to Drug Plans

CVS Health announced it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option and begin coverage for the drugmaker's newly approved obesity pill, Forza.

May 28, 2026·2 sources
00
May 26, 2026

Eli Lilly Acquires Three Vaccine Developers, Expanding Infectious Disease Portfolio

Eli Lilly is acquiring three small vaccine developers, marking a significant expansion into infectious disease vaccines and providing a boost to the vaccine development field.

May 26, 2026·1 source
00
May 25, 2026

Eli Lilly's Gene-Editing Therapy Reduces Cholesterol by 62% in Early Clinical Trial

Eli Lilly reported that a high dose of its gene-editing therapy from Verve Therapeutics reduced cholesterol levels by 62% in participants in an early-stage clinical trial, representing a significant advance in gene-editing treatments for cardiovascular disease.

May 25, 2026·1 source
00
May 22, 2026

Longevity Startup Retro Biosciences Raises Funding at $1.8 Billion Valuation

Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, announced it has raised additional funding at a $1.8 billion valuation, marking significant investor confidence in the anti-aging research space.

May 22, 2026·1 source
00
May 21, 2026

Eli Lilly's Retatrutide Achieves Up to 30% Weight Loss in Phase 3 TRIUMPH-1 Trial

Eli Lilly announced positive results from its Phase 3 TRIUMPH-1 trial showing retatrutide, an experimental triple-agonist obesity drug, achieved average weight loss of 28.3% at 80 weeks and 30.3% at 104 weeks on the highest dose, matching weight reduction levels typically seen with bariatric surgery.

May 21, 2026·3 sources
00
May 18, 2026

Trump Invested in Eli Lilly Stock as Administration Boosted Obesity Drug Policies

New ethics disclosures reveal President Trump purchased stock in Eli Lilly and an injectable device manufacturer while his health agencies implemented policies benefiting these companies' obesity drug products.

May 18, 2026·1 source
00
May 16, 2026

AstraZeneca's Imfinzi-Enfortumab Vedotin Combination Shows Historic Survival Gains in Bladder Cancer Trial

AstraZeneca's VOLGA trial confirms that the Imfinzi EV combination significantly improves overall survival for cisplatin-ineligible bladder cancer patients, representing a major advancement in treatment for this difficult-to-treat population.

May 16, 2026·1 source
00
May 15, 2026

Takeda Pharmaceuticals Settles Kickback Allegations for $13.6 Million

Takeda Pharmaceuticals agreed to pay $13.6 million to settle allegations that it paid kickbacks to doctors to prescribe an antidepressant, representing enforcement action against pharmaceutical industry practices.

May 15, 2026·1 source
00
May 14, 2026

Biogen Advances Tau-Targeting Alzheimer's Drug to Phase 3 Despite Mixed Phase 2 Results

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies following a Phase 2 trial that showed mixed results.

May 14, 2026·1 source
00

CREATE Medicines Raises $122 Million for CAR-T Therapy Development

CREATE Medicines secured $122 million in funding to advance its CAR-T therapy candidates through human trials, alongside a company rebrand and expanded pipeline.

May 14, 2026·1 source
00
May 12, 2026

Bristol Myers Squibb Partners with China's Hengrui Pharma on Dozen Drugs in $15.2B Deal

Bristol Myers Squibb and China's Hengrui Pharma announced a partnership to advance more than a dozen early-stage drugs in a deal worth up to $15.2 billion.

May 12, 2026·1 source
00
May 9, 2026

Roche to Acquire AI Pathology Company PathAI for $750 Million

Roche has signed a deal to acquire PathAI, an artificial intelligence company focused on helping pathologists diagnose diseases, for $750 million to accelerate its use of AI in diagnostics.

May 9, 2026·1 source
00
May 7, 2026

Novo Nordisk Reports Positive Earnings on Oral Wegovy Development Progress

Novo Nordisk's stock price and earnings received a boost following less-negative news about the development of an oral version of its blockbuster weight loss drug Wegovy, marking progress in the company's efforts to create a pill formulation.

May 7, 2026·1 source
00
May 5, 2026

Cytokinetics' Heart Disease Drug Myqorzo Meets Primary Endpoints in Phase 3 Trial for Genetic Heart Condition

Cytokinetics announced its heart disease drug Myqorzo, already approved in one indication, succeeded in meeting twin efficacy goals in a Phase 3 trial for genetic heart disease, potentially boosting future sales.

May 5, 2026·1 source
00

Johnson & Johnson's IBD Therapy Fails to Meet Primary Endpoint in Clinical Trial

Johnson & Johnson's closely watched inflammatory bowel disease therapy failed to show statistically significant improvement in patients during clinical trials, representing a setback for the pharmaceutical giant's gastroenterology pipeline.

May 5, 2026·1 source
00

UCB Acquires Maker of Antibody Treatments for Autoimmune Diseases

Belgian pharmaceutical company UCB has announced the acquisition of a company specializing in antibody treatments for autoimmune diseases, expanding its immunology portfolio.

May 5, 2026·1 source
00

French Regulator Fines Novo Nordisk and Eli Lilly Over Weight Loss Drug Ad Campaigns

France's medicines regulator has imposed fines on Novo Nordisk and Eli Lilly for their weight loss drug advertising campaigns, marking a significant regulatory action against the pharmaceutical giants' marketing practices.

May 5, 2026·1 source
00
May 4, 2026

Atrium Health Proposes Acquisition of WakeMed in Major North Carolina Hospital Consolidation

Atrium Health, one of the nation's largest hospital networks, has proposed acquiring the Raleigh-based WakeMed system. State and local officials are pressing for a delay on the deal, which became public on May 1.

May 4, 2026·2 sources
00

Latus Bio Raises $42 Million to Advance Huntington's Disease Gene Therapy Trial

Latus Bio secured $42 million in funding as it prepares to seek FDA approval to begin a clinical trial for its gene therapy targeting Huntington's disease, a progressive neurodegenerative disorder.

May 4, 2026·1 source
00
May 3, 2026

Eli Lilly Raises 2026 Guidance as GLP-1 Drug Demand Surges in Q1

Eli Lilly reported strong Q1 2026 financial results driven by massive growth in Mounjaro and Zepbound sales, leading the company to raise its full-year guidance amid surging demand for GLP-1 medications.

May 3, 2026·1 source
00
May 2, 2026

FDA Approves Merck's Idvynso, New Once-Daily Two-Drug HIV Treatment Tablet

The FDA has approved Merck's Idvynso (doravirine/islatravir), a once-daily, two-drug single tablet for treating HIV-1 infection in adults to replace current antiretroviral regimens in virologically suppressed patients.

May 2, 2026·1 source
00
Apr 29, 2026

AstraZeneca Commits $405M to UK Expansion Following US-UK Pharma Deal

AstraZeneca commits $405 million to expand operations in the United Kingdom following a new US-UK pharma agreement, signaling increased investment and strategic alignment across transatlantic drug markets.

Apr 29, 2026·2 sources
00
Apr 28, 2026

Eli Lilly Partners with AI Startup Profluent to Develop Next-Generation Gene Editors Beyond CRISPR

Eli Lilly has entered a deal with AI startup Profluent to develop AI-designed enzymes capable of inserting entire genes, moving beyond traditional CRISPR technology. The partnership aims to reshape genetic medicine by using artificial intelligence to create novel gene editing tools.

Apr 28, 2026·1 source
00
Apr 27, 2026

Mark Cuban’s Cost Plus Drugs Targets Employer Health Costs With New Plan

Cost Plus Drugs introduces a new strategy to partner with employers, aiming to lower prescription drug costs through transparent pricing and direct distribution models.

Apr 27, 2026·2 sources
00
Apr 22, 2026

Roche Presents Multiple Sclerosis Drug Data Ahead of Regulatory Submission

Swiss drugmaker Roche presented latest clinical trial data for its experimental multiple sclerosis drug at a major conference, setting the stage for regulatory approval submissions, though safety questions remain under scrutiny.

Apr 22, 2026·1 source
00
Apr 21, 2026

BioAge Labs Reports Experimental Cardiovascular Drug Significantly Reduced Inflammation in Early Study

BioAge Labs announced its investigational pill for cardiovascular risk prevention significantly reduced inflammation markers in an early-stage clinical study, representing potential progress in heart disease prevention.

Apr 21, 2026·1 source
00
Apr 20, 2026

FDA Approves At-Home Starting Dose for Eisai-Biogen Alzheimer's Drug

The U.S. Food and Drug Administration approved an at-home starting dose of Eisai and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver rather than requiring initial doses in a clinical setting.

Apr 20, 2026·2 sources
00

CVS Caremark Settles with FTC Over Drug Rebate Practices, Agrees to Count TrumpRx Purchases Toward Deductibles

CVS Health's Caremark pharmacy benefits unit reached a settlement with the U.S. Federal Trade Commission to curb controversial rebate practices in the pharmacy benefits market. The agreement requires Caremark to count consumer purchases from Trump's TrumpRx program toward insurance deductibles, mirroring a similar settlement previously reached with Cigna.

Apr 20, 2026·4 sources
00
Apr 17, 2026

Roche Launches New Phase 3 Trial of Elevidys for European Approval

Roche is initiating another Phase 3 clinical trial of the controversial Duchenne muscular dystrophy gene therapy Elevidys, aiming for potential approval in European markets.

Apr 17, 2026·1 source
00
Apr 16, 2026

FDA Petition Seeks to Revoke Approval of Roche's Ocrevus for Primary Progressive Multiple Sclerosis

The FDA is reviewing a petition to revoke approval of ocrelizumab (Ocrevus), Roche's top-selling drug, for treating primary progressive MS, raising questions about whether the drug may be causing more harm than good in this patient population.

Apr 16, 2026·1 source
00

FDA Requests Additional Liver Injury Data on Eli Lilly Obesity Pill Foundayo

The FDA has asked Eli Lilly for more data on liver injury linked to its newly approved obesity pill Foundayo.

Apr 16, 2026·1 source
00

Report Finds Drugmakers Raised Prices Despite Trump Deals

Senate Democrats’ report finds pharmaceutical companies increased prices on hundreds of medications despite prior agreements intended to limit drug cost growth, raising concerns about enforcement and policy effectiveness.

Apr 16, 2026·3 sources
00
Apr 14, 2026

FDA Pushes Drugmakers to Report Missing Clinical Trial Results

FDA officials revealed that nearly 30% of clinical trial studies highly likely to fall under mandatory reporting requirements failed to submit results, prompting new enforcement efforts to improve transparency.

Apr 14, 2026·1 source
00
Apr 11, 2026

Biotech Venture Capital Model Faces Disruption as Traditional Formula Under Pressure

The tried-and-true venture capital approach to biotech investing that has worked for decades is being disrupted, forcing VCs to reconsider their traditional drug development funding strategies.

Apr 11, 2026·3 sources
00
Apr 7, 2026

Gilead Acquires German Cancer Biotech Tubulis for Over $3 Billion

Gilead Sciences is acquiring German biotech company Tubulis for more than $3 billion in a deal that will expand its oncology pipeline with antibody-drug conjugate technology.

Apr 7, 2026·1 source
00

Novo Nordisk Launches High-Dose Wegovy for Weight Loss

Novo Nordisk has launched a higher-dose version of its obesity medication Wegovy, intensifying competition in the rapidly growing weight loss drug market.

Apr 7, 2026·1 source
00

Merck's Experimental HIV Prevention Pill Could Be Manufactured for Under $5 Annually, Researchers Say

Researchers published findings that Merck's experimental HIV prevention pill could be produced for less than $5 per year, urging the company to urgently begin licensing generic production to improve global access.

Apr 7, 2026·1 source
00
Apr 6, 2026

FDA Delay Forces Small Biotech Company to Shut Down Operations

A small biotech company was forced to wind down operations after the FDA abruptly postponed a key meeting for four months, despite reaching a clinical trial agreement in February that came too late.

Apr 6, 2026·2 sources
00

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion

Neurocrine Biosciences is acquiring Soleno Therapeutics in a $2.9 billion deal to gain an approved medicine for a rare disease that causes insatiable hunger.

Apr 6, 2026·1 source
00
Apr 4, 2026

Trump Administration Negotiates Drug Pricing Deals with Smaller Pharmaceutical Companies

The White House is negotiating new drug-pricing agreements with smaller biotechnology companies facing the threat of 100% tariffs on imported medicines, according to multiple sources with knowledge of the meetings.

Apr 4, 2026·1 source
00
Apr 2, 2026

CDC Pauses Diagnostic Testing for Rabies, Monkeypox and Other Infectious Diseases During Agency Evaluation

The Centers for Disease Control and Prevention has suspended laboratory testing for rabies, monkeypox, and numerous other infectious diseases as part of an ongoing evaluation following recent agency downsizing.

Apr 2, 2026·1 source
00

FDA Approves Eli Lilly's Obesity Pill, Setting Up Competition with Novo Nordisk

The FDA has approved Eli Lilly's oral obesity medication, marking a significant development in the weight-loss drug market and positioning it for direct competition against Novo Nordisk's Wegovy pill.

Apr 2, 2026·1 source
00
Apr 1, 2026

Whoop Valued at $10 Billion After $575 Million Fundraising Round

Health and fitness tracking wristband maker Whoop raised $575 million from investors including Mayo Clinic and Qatar's sovereign wealth fund, reaching a $10 billion valuation.

Apr 1, 2026·2 sources
00
Mar 31, 2026

Eli Lilly Acquires Centessa Pharmaceuticals for $6.3 Billion to Gain Narcolepsy Drug

Eli Lilly announced the acquisition of Centessa Pharmaceuticals in a deal worth at least $6.3 billion, gaining access to a promising narcolepsy treatment as part of its expansion strategy.

Mar 31, 2026·1 source
00
Mar 30, 2026

Takeda Pharmaceuticals to Lay Off Nearly 250 Workers in Cambridge Beginning July

Takeda Pharmaceuticals, the largest biopharma employer in Massachusetts, will lay off approximately 250 workers at its Cambridge location starting in July as part of broader job cutting measures.

Mar 30, 2026·1 source
00
Mar 29, 2026

Eli Lilly Expands AI Drug Discovery Partnership with Insilico Medicine in Deal Worth Up to $2.75 Billion

Pharmaceutical giant Eli Lilly has agreed to a global licensing and research collaboration with AI drug developer Insilico Medicine, providing $115 million upfront with potential total value reaching $2.75 billion. The deal expands an existing partnership focused on using artificial intelligence for drug discovery.

Mar 29, 2026·4 sources
00
Mar 26, 2026

FDA Approves Rocket Pharmaceuticals Gene Therapy for Rare Immune Disorder

The FDA approved Kresladi, Rocket Pharmaceuticals' gene therapy for a rare immune disorder, despite testing in only nine patients. The approval represents a notable decision as the agency has recently taken tougher stances on rare disease drugs.

Mar 26, 2026·3 sources
00
Mar 25, 2026

FDA Approves Johnson & Johnson's Icotyde for Moderate-to-Severe Plaque Psoriasis

The U.S. Food and Drug Administration has approved Johnson & Johnson's Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis in adults.

Mar 25, 2026·1 source
00

Merck to Acquire Terns Pharmaceuticals for $6.7 Billion

Merck announced it will acquire Terns Pharmaceuticals for $6.7 billion to gain access to a promising leukemia treatment. The deal represents Merck's effort to secure its next generation of blockbuster drugs.

Mar 25, 2026·2 sources
00
Mar 24, 2026

FTC Reaches Settlement with CVS Over PBM Insulin Price Manipulation

The Federal Trade Commission struck a proposed settlement with CVS over charges that its pharmacy benefit manager manipulated insulin prices and impeded patient access. The FTC estimates the settlement will save Americans up to $7 billion in out-of-pocket costs over 10 years.

Mar 24, 2026·1 source
00

Top claims

  • ▪Hengrui said Novo Nordisk will acquire the development, manufacturing, and commercialization rights for the experimental drug HRS-1596 outside of mainland China, Taiwan, Macao, and Hong Kong
  • ▪A spokesperson for Novo Nordisk stated that the company plans to conduct global trials for the HRS-1596 asset, but declined to provide specific timelines
  • ▪Drugmakers including Novo Nordisk and Eli Lilly believe oral weight-loss pills could attract patients who are reluctant to use injectable treatments

People involved

Susan CollinsRobert F. Kennedy Jr.Donald TrumpWilliam RutoBryan Thompson

Subtopics

Drug Policy, Pricing & Approval141Drug Approval and Clinical Trials121Clinical trials50Pharmaceutical Industry37Lifestyle, Wellness and Nutrition28Weight loss medications & GLP-1 drugs24GLP-1 medications21Clinical Trial Design & Evaluation20Public healthcare20Weight management20Drug development18Cancer & Oncology16Government and Regulatory Policy16Clinical evaluation15Eli Lilly15Novo Nordisk13US health policy & drug pricing12Cancer treatment11Medication Pricing & Affordability11US healthcare regulation11Healthcare Policy10Infectious Disease and Outbreaks10Mergers & acquisitions (M&A)10Obesity treatment10

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories